drugset
drugset / Trial / NCT00277303

Study of XL999 in Patients With Metastatic Colorectal Cancer

NCT00277303 ↗

Phase 2 Terminated 17 enrolled Symphony Evolution, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with metastatic colorectal cancer (CRC). XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.

Timeline

Start
2005-12
Primary completion
2006-08
Completion
2007-02

Outcome

Outcome not reported

Stopped: “Study was terminated due to cardiac toxicities in the subjects”

Drugs

EvaluationDrugModalityDoseRoute
Subject XL999 Small molecule 2.4 mg/kg Intravenous

Indications

colorectal cancer